LGVN
LGVN clinical trials: Longeveron Inc.
Every trial on ClinicalTrials.gov where Longeveron Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LGVN on the catalyst calendar · LGVN registry changes
- Primary completion Jun 30, 2026Sponsor estimatePhase 2NCT04925024Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.Longeveron Inc. · Hypoplastic Left Heart SyndromeActive, not recruitingLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2023ActualPhase 2NCT05233774Lomecel-B Effects on Alzheimer's DiseaseLongeveron Inc. · Mild Alzheimer's DiseaseCompletedLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2024Sponsor estimatePhase 1NCT04629105Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)Longeveron Inc. · ARDS, HumanUnknown statusLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2024Sponsor estimatePhase 1/Phase 2NCT03525418Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)Longeveron Inc. · HLHSUnknown statusLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2023Sponsor estimatePhase 2NCT02587572Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA TrialLongeveron Inc. · Metabolic DiseaseWithdrawnLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2021ActualPhase 1/Phase 2NCT02982915Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging FrailtyLongeveron Inc. · Aging FrailtyCompletedLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2021ActualPhase 2NCT03169231Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging FrailtyLongeveron Inc. · Aging FrailtyCompletedLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2020ActualPhase 1NCT02600130Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's DiseaseLongeveron Inc. · Alzheimer's DiseaseCompletedLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2019ActualPhase 1NCT02398604Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart SyndromeLongeveron Inc. · Hypoplastic Left Heart SyndromeTerminatedLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2019ActualPhase 1/Phase 2NCT02065245AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS DeliveryLongeveron Inc. · FrailtyCompletedLGVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner